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HIGHLIGHTS
• Compounds that interact with multiple targets but minimally with the cytochrome P450
system (CYP) address the many factors leading to neurodegeneration.
• Acetyl- and Butyryl-cholineEsterases (AChE, BChE) and Monoamine Oxidases A/B
(MAO A, MAO B) are targets for Multi-Target Designed Ligands (MTDL).
• ASS234 is an irreversible inhibitor of MAO A >MAO B and has micromolar potency
against the cholinesterases.
• ASS234 is a poor CYP substrate in human liver, yielding the depropargylated
metabolite.
• SMe1EC2, a stobadine derivative, showed high radical scavenging property, in vitro
and in vivo giving protection in head trauma and diabetic damage of endothelium.
• Control of mitochondrial function and morphology by manipulating fission and fusion
is emerging as a target area for therapeutic strategies to decrease the pathological
outcome of neurodegenerative diseases.
Growing evidence supports the view that neurodegenerative diseases have multiple and
common mechanisms in their aetiologies. These multifactorial aspects have changed
the broadly common assumption that selective drugs are superior to “dirty drugs” for
use in therapy. This drives the research in studies of novel compounds that might
have multiple action mechanisms. In neurodegeneration, loss of neuronal signaling is
a major cause of the symptoms, so preservation of neurotransmitters by inhibiting the
breakdown enzymes is a first approach. Acetylcholinesterase (AChE) inhibitors are the
drugs preferentially used in AD and that one of these, rivastigmine, is licensed also for
PD. Several studies have shown that monoamine oxidase (MAO) B, located mainly in
glial cells, increases with age and is elevated in Alzheimer (AD) and Parkinson’s Disease’s
(PD). Deprenyl, a MAO B inhibitor, significantly delays the initiation of levodopa treatment
in PD patients. These indications underline that AChE and MAO are considered a
necessary part of multi-target designed ligands (MTDL). However, both of these targets
are simply symptomatic treatment so if new drugs are to prevent degeneration rather
than compensate for loss of neurotransmitters, then oxidative stress and mitochondrial
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events must also be targeted. MAO inhibitors can protect neurons from apoptosis by
mechanisms unrelated to enzyme inhibition. Understanding the involvement of MAO
and other proteins in the induction and regulation of the apoptosis in mitochondria
will aid progress toward strategies to prevent the loss of neurons. In general, the
oxidative stress observed both in PD and AD indicate that antioxidant properties are
a desirable part of MTDL molecules. After two or more properties are incorporated into
one molecule, the passage from a lead compound to a therapeutic tool is strictly linked
to its pharmacokinetic and toxicity. In this context the interaction of any new molecules
with cytochrome P450 and other xenobiotic metabolic processes is a crucial point. The
present review covers the biochemistry of enzymes targeted in the design of drugs
against neurodegeneration and the cytochrome P450-dependent metabolism of MTDLs.
Keywords: multi target designed ligands, mitochondria, oxidative stress, monoamine oxidase, cytochrome P450,
neurodegeneration
INTRODUCTION
Neurodegeneration is a complex process that can arise from
many different defects or insults. In the last five years at least
80 reviews with “neurodegeneration” in the title have appeared,
each covering different aspects of the processes involved. These
include protein aggregation, mitochondrial movement, and
function, dysregulation of microRNA, iron accumulation,
inflammation, defects in proteins such as sirtuins or tau,
dysregulation of protein trafficking or breakdown, and oxidative
stress (Donmez, 2012; Gascon and Gao, 2012; Schipper, 2012;
Sheng and Cai, 2012; Costanzo and Zurzolo, 2013; Butterfield
et al., 2014; Moussaud et al., 2014; Rao et al., 2014; Wang
X. et al., 2014; Witte et al., 2014; Goedert, 2015; Sankowski
et al., 2015). With such complexity, it has proved difficult to
identify biomarkers to quantify progression and targets to block
to prevent the degeneration. The most obvious physiological
symptoms are the loss of neurons in Alzheimer’s Disease
(AD) and Parkinson’s Disease (PD) with the consequently
lower neurotransmitter levels, and the formation of protein
aggregates in all forms of neurodegeneration. These observations
provided the primary targets to date, namely enzymes catalyzing
neurotransmitter breakdown (cholinesterases, ChE; monoamine
oxidases, MAO; catechol-O-methyltransferase, COMT),
prevention of production of amyloid beta (Aβ) by beta-secretase,
of protein aggregation, and of oxidative damage known to stress
cells to the point of apoptosis (Guzior et al., 2015; Swomley
and Butterfield, 2015). Intervention in the potentially damaging
outcomes of oxidation stress either by means of upstream
(prevention of free radical generation) or downstream (free
radical scavenging) antioxidant pathways helps preserve neurons
and slow neurodegeneration (Uttara et al., 2009).
Related to oxidative damage and because of their role in
the regulation of apoptosis, mitochondria are a current active
Abbreviations: AD, Alzheimer’s Disease; AChE, acetylcholinesterase; Aβ, amyloid
beta; BChE, butyrylcholinesterase; MAO, monoamine oxidase; CYP, cytochrome
P450; AIF, apoptosis inducing factor; MTDL, multi-target designed ligand; PD,
Parkinson’s Disease; ROS, Reactive Oxygen Species; CI Complex I, HLM, human
liver mitochondria; RLM, rat liver mitochondria.
area of investigation both for generation of reactive oxygen
species (ROS) or inefficient energy production that limits
defenses against ROS. Recent advances focus on mitochondrial
movement, fusion, and fission and interactions with the cytosol
(including specific proteins related to neurodegeneration such
as the Bax/Bid family and sirtuins) (Eckert et al., 2012; Johri
and Beal, 2012). Mitochondria play a central role in the
oxidative metabolism of nutrients and ATP synthesis. They
also contribute to intracellular second messenger homeostasis
(Ca2+ and ROS), and are determinant for both cell survival
and apoptotic cell coordination (Waagepetersen et al., 2003;
Mandemakers et al., 2007; Nunnari and Suomalainen, 2012;
Bernardi et al., 2015). Mitochondrial dysfunction is frequently
proposed to be involved in neurodegenerative pathogenesis,
including PD and AD (Mandemakers et al., 2007; Moreira
et al., 2010; Correia et al., 2012a,b; Perier et al., 2012; Perier
and Vila, 2012). With their high energy demands neurons
are particularly dependent on mitochondrial ATP generation,
and are thus intolerant of mitochondrial dysfunction (Lezi
and Swerdlow, 2012). This makes the understanding of the
mitochondrial mechanisms underlying these pathologies critical
for designing more effective strategies to halt or delay disease
progression (Correia et al., 2010a,b). An alternative strategy to
preserving levels of neurotransmitters by inhibiting breakdown
is the pharmacological stimulation of the post-synaptic receptors
in the remaining neurons. Most receptors are G-protein coupled
receptors (http://www.guidetopharmacology.org/), an area of fast
recent progress with the determination of receptor structures,
such as the muscarinic acetylcholine receptors (Thal et al.,
2016), the availability of cloned receptors for pharmacology
and compound screening (Katritch et al., 2013; Melancon
et al., 2013), and new methods for assessing the complex
function of the receptors (van Unen et al., 2015). Here too,
multiple targets are attractive: for example, first-in-class dual
M1/M4 agonists now in preclinical development (http://www.
heptares.com/pipeline/). Antagonists to histamine receptors are
also interesting to prevent the inflammation also thought
to contribute to neurodegeneration (Vohora and Bhowmik,
2012; Walter and Stark, 2012). However, a meta-analysis of
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placebo-controlled trials for H3 receptor antagonists did not find
significant effects on cognition (Kubo et al., 2015). Receptors will
not be further mentioned in this article because we focus on
intracellular targets.
It is apparent from the above outline that the primary causes
of neurodegeneration are not easily defined, and will almost
certainly be due to highly individual combinations of factors.
This has led to the search for novel compounds that will
interact with multiple targets, and have antioxidant properties
as part of the desired pharmacologic profile. For the future
there will be a need for various combinations of multi-target
designed ligands (MTDL) to meet the needs of each individual
combination of defects. In this article, we shall describe the
background to in vitro assessment of compounds to combat
neurodegeneration, considering the current targets either for
symptomatic treatment (AChE and MAO) or to prevent or
reverse deterioration (anti-oxidants or mitochondrial function),
and giving examples of compounds from our own work
conducted in collaborations facilitated by COST Action CM1103
“Structure-based drug design for diagnosis and treatment
of neurological diseases: dissecting and modulating complex
function in the monoaminergic systems of the brain.”
Screening techniques highlight that many enzymes and
receptors interact with a given chemical. This is clear in
off-target data-mining (Nikolic et al., 2015; Hughes et al.,
2016) and in high throughput screens (Sipes et al., 2013). In
the latter project aimed at building a resource of biological
pathways of toxicity for various types of chemicals, 976
compounds known as pharmaceuticals, food additives or
pesticides were tested for inhibition or activation of enzymes
and for binding to monoaminergic transporters and receptors.
The most common sub-micromolar interactions were with the
cytochrome P450 (CYP) family, transporters, the mitochondrial
translocator (benzodiazepine–binding) protein, the dopamine
and serotonin reuptake carriers, and the aminergic G-protein
coupled receptors, and MAO was also in the top 20 most
promiscuous proteins. These results indicate the promise of
MTDL for cholinesterase (lower on that list) and MAOs or to
include receptor agonism or antagonism into one molecule is
not without the drawback of also finding off-target activity. In
particular, any effect on the metabolic CYP enzymes must be
carefully appraised.
After the identification of the target, be it receptor or enzyme,
a variety of empirical and/or in silico studies are conducted in
order to vary the structure to increase the pharmacological effects
of the new compounds. However, good in vitro activity may
not correspond to a therapeutic effect, unless the molecule also
possesses high bioavailability and low toxicity. This means that
the new compoundsmust have good pharmacokinetic properties.
The investigation on absorption, distribution, metabolism and
excretion properties and toxicological profiling (ADME/Tox)
have become an essential step in early drug discovery that
has demonstrated a high impact on the successful progression
of drug candidates. Growing knowledge of the key roles that
pharmacokinetics and drug metabolism play as determinants
of in vivo drug action, has led many researchers, drug
companies and regulatory agencies to include examination of
pharmacokinetics and drug metabolism properties as part of
their process in the selection of drug candidates. In this context,
the role of the CYP isoenzymes is outlined, since it represents
a major source of variability toward pharmacokinetics and
pharmacological responses in this phase.
In this review we consider the biochemistry of some of the
key pharmacological targets of MTDL, giving selected examples
from our own expertise. The traditional key targets in Alzheimer’s
Disease (AD), the ChEs and MAOs, are described first, then the
new and diverse potential targets in mitochondrial function for
cell survival, followed by an example of targeting the oxidative
stress that is seen in a variety of degenerative conditions. Lastly
in this overview of metabolic aspects of drug design, the action
of the CYP isoezymes, important for effectiveness of all drugs in
vivo, on MTDL is described.
ADDRESSING THE PATHOLOGY OF
NEURODEGENERATION: THE TARGETS
CONSIDERED HERE
Four of the five drugs ever approved to treat symptoms of
memory loss and confusion in AD patients are cholinesterase
inhibitors. The cholinergic hypothesis of AD posits that the
cognitive and behavioral dysfunctions of AD result from deficits
in acetylcholine neurotransmission. These early symptoms can
be ameliorated by inhibiting the cholinesterases to prolong the
presence of acetylcholine in the synapse. However, cholinesterase
activities have also been reported correlate with the density of
amyloid plaque deposition in the AD brain (Arendt et al., 1992).
The mechanism by which AChE and to a lesser extent BChE
facilitate plaque deposition is still being investigated (Hou et al.,
2014).
The other catabolic enzyme that is inhibited to maintain
decreasing neurotransmission is MAO, located on the cytosolic
face of the mitochondrial outer membrane where it is attached
by a single membrane-spanning helix. To be metabolized by
MAO, monoamine neurotransmitters must be taken up into the
cells. The two forms, MAO A and MAO B, are co-located in
liver mitochondria, but otherwise have very different expression
patterns. MAO A is the major form in the intestine and placenta,
MAO B in platelets. In the brain, MAO B is expressed in the glia
and in serotonergic neurons, whereas MAO A predominates in
all other neurons.
Mitochondria produce the majority of energy in all type of
cells but particularly in neurons where the energy demand for
neurotransmission is high. Deficits in mitochondrial function
(i.e., increased oxidative stress, decreased efficiency of the
respiratory chain, apoptosis dysfunctions, deregulation of fusion
and fission processes) have been found in all neurodegenerative
conditions. Understanding the mechanisms underlying these
pathologies is critical to designingmore effective strategies to halt
or delay disease progression (Correia et al., 2010a, 2012a). Each
of the mitochondrial functions is closely related to the others
and alteration in any of them might develop neurodegeneration,
making difficult to discriminate which changes are more critical
(Haddad and Nakamura, 2015). Abnormal morphology, altered
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dynamics, and biochemical dysfunction of mitochondria are
usually observed, being often systemic rather than brain-limited
(Lezi and Swerdlow, 2012).
Mitochondrial respiratory capacity and efficient ATP
production are vital for neuronal survival. In most
neurodegenerative conditions mutations accumulate in
mitochondrial DNA (encoding 13 proteins essential for
respiratory chain function), the enzymatic activity of respiratory
chain enzymes is altered and oxidative stress usually increases
(Goldberg et al., 2002). Such dysfunctions arise not only as
consequence of mutations in mitochondrial DNA but can also be
due to mutations in nuclear DNA encoding for proteins either
imported to or interacting with the mitochondria. Changes
in the mitochondrial membrane potential and the increased
reactive oxygen species (ROS) associated with electron transport
chain dysfunction have been strongly linked to reduced cell
viability (Bird et al., 2014). Although ROS formation is a natural
by-product of mitochondrial respiration, overproduction is
indicative of cell stress (Murphy, 2009). Antioxidant therapy
has therefore long been sought to combat aging as well as
neurodegeneration.
Antioxidant compounds can either react with radicals to
prevent damage to biological molecules (proteins, lipids or DNA)
or can complex metal ions to decrease generation of ROS.
Iron ions are the well-established target in AD, playing a key
catalytic role in the Fenton reaction (reviewed in Unzeta et al.,
2016). Knock out studies have established that loss of Amyloid
Precursor Protein (APP) or tau (both AD-linked proteins) results
in iron accumulation in the brain. Iron is bound to ferritin,
a protein that increases with age and in AD (Bartzokis and
Tishler, 2000). Iron is found also in plaques (Meadowcroft et al.,
2009). Iron-chelation capability is part of the action spectrum
of rasagiline used for treatment of PD (Weinreb et al., 2016)
and a highly desirable addition to future MTDL compounds for
prevention of neurodegeneration.
Lastly, decreasing the generation of aberrant proteins,
preventing their aggregation, and blocking down-stream events
are developing targets. The prevention of production of amyloid
beta (Aβ) by inhibition of the beta-secretases already has
led to candidate small molecule compounds in clinical trials
(Yan and Vassar, 2014; Yan et al., 2016). The acceleration
of Aβ aggregation by the peripheral site of AChE has long
been recognized (Inestrosa et al., 1996; Reyes et al., 1997)
and is an important component of effective AChE inhibitors
designed to combat AD (Bartolini et al., 2003; Anand and
Singh, 2013; Bolea et al., 2013; Bautista-Aguilera et al., 2014a;
Hebda et al., 2016). Deleterious intracellular effects of Aβ are
also recognized, such as the consequences of Aβ binding to a
17-β-hydroxysteroid dehydrogenase known as Amyloid Binding
Alcohol Dehydrogenase (ABAD), a tetrameric mitochondrial
enzyme that catalyzes the oxidation of steroids. ABAD is
decreased in AD (Lustbader et al., 2004) and missense mutations
in its gene (HSD17B10) result in alteration of mitochondria
morphology and neurodegeneration in infancy (Yang et al.,
2014). The ABAD-Aβ interaction is associated with up-
regulation of endophilin, a protein important for membrane-
shaping in processes such as synaptic vesicle formation which
might contribute to neuronal sensitivity to ABAD-Aβ complex
formation inside neuronal mitochondria (Borger et al., 2013).
Drug discovery to prevent the ABAD-Aβ interaction, begun with
brain-permeant peptides (Borger et al., 2013), is now moving
to small molecules (Valaasani et al., 2014; Benek et al., 2015;
Hroch et al., 2015) that will provide information for future
incorporation into multi-target compounds.
The aim of MTDL design is to combine features that can
interact with two or more of the desired targets (Csermely
et al., 2005; Geldenhuys et al., 2011; Hughes et al., 2016). This
expands the biological screening required at the early stages for
hit discovery and lead optimization. With structures of most
targets available, in silico screening is a useful tool for examining
large chemical databases (Hughes et al., 2016; Nikolic et al., 2016).
Combining known drugs for each target into one molecule has
also produced promising compounds by incorporating elements
of proven inhibitors for each target into new multi-potent
molecules (Bolognesi et al., 2007; Piazzi et al., 2008; Zhu et al.,
2009; Kupershmidt et al., 2012; Luo et al., 2013; Sun et al., 2014;
Bautista-Aguilera et al., 2014b; Wang L. et al., 2014; Pisani et al.,
2016; Weichert et al., 2016; Xie et al., 2016). One example that
progressed to clinical trials against AD is ladostigil, designed
to inhibit MAOs and ChEs but also incorporating potent anti-
apoptotic and neuroprotective activities (Weinreb et al., 2012;
Youdim, 2013). The next sections in this review will consider
other examples of MTDL in the context of some of these targets
of interest for AD drugs.
NEUROTRANSMITTER DEGRADING
ENZYMES
Enzyme Inhibitors—Pharmacological
Characterization
The development of novel drugs that target enzymes requires
an understanding of enzyme mechanism and is deeply informed
by detailed knowledge of the protein structure. Understanding
how enzymes (or indeed receptors) work is vital for medicinal
chemists aiming to design new drugs (Walsh, 2013). In the very
first stage of evaluation of new compounds in a biological system,
the medicinal chemistry shortcut of IC50 measurement is an
invaluable tool for comparisons of series of derivatives on a given
scaffold and provides useful information for determining a hit
or for choice of a lead compound. It is a measurement that can
be used for both simple and complex biological systems but it
is important to recognize that the meaning of IC50 (as opposed
to its definition as 50% inhibition of a measured parameter)
changes according to the system and the assay conditions. In the
context of measurement of a single enzyme activity, IC50 is not
affinity for a target but simply the concentration of the compound
that inhibits the activity by 50% under the specific conditions
used. For more informative data on enzyme reversible inhibitors,
the Ki (the inhibition constant independent of the substrate
concentration used) and the mechanism of inhibition should be
determined. For irreversible inhibitors, the rate of inactivation
and the concentration dependence are needed (McDonald and
Tipton, 2012). It should be recognized that IC50 values for
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reversible and irreversible inhibitors are not directly comparable
because of the time element. The initial reversible binding of
an inactivating inhibitor can only be compared with reversible
inhibitors (or indeed binding constants from docking) if initial
rates are measured in an assay where the enzyme is added last to
a mixture of substrate and inhibitor.
When comparing alternate targets, care is needed to use
conditions for each target that will allow comparison. Selective
inhibition of MAO A and MAO B is often desired, but they
have different KM values for their common substrates (the
concentration of substrate required to give half the maximum
velocity), so are saturated to different degrees at any one
concentration. For example, purified human MAO A activity
reaches 50% of its maximum at 0.15 mM kynuramine, whereas
MAO B reaches 50% of maximum rate with only 0.08 mM
kynuramine. With reversible inhibitors,
E+ I↔ EI but during steady state measurement, when E+ S
↔ ES→ E+ P, the concentration of free enzyme (E) available to
bind inhibitor is not the total enzyme added but rather a fraction
of the total that depends on the substrate concentration used
and the relative values of the rate constants. In the steady-state
where ES is constant, MAO A assayed with 0.1 mM kynuramine
has 60% of free enzyme but MAO B has only 44% available for
inhibitor binding. For an inhibitor of both with the same Ki of
0.01 mM, the IC50 would be measured as 17 µM for MAO A but
22.5 µM for MAO B despite the fact that the inhibitor bound
equally well to both enzymes. Simply using an assay with fixed
substrate concentration without taking into account the different
KM values would therefore introduce a 30% bias to the selectivity.
The mechanism of the enzyme can also influence IC50 values.
This is seen in the kinetic analysis of MAO B where it is clear
that there are two forms of the enzyme that can bind the ligand
(substrate or inhibitor), namely, the oxidized or the reduced
forms, and that these two forms bind ligands with different
affinities. Since different substrates give different proportions
of these forms during steady-state catalysis, different Ki values
for an inhibitor can be obtained from different substrates.
Overall, care must be exercised in choice of substrate and of
assay conditions to obtain reliable IC50 values, but only kinetic
constants can be considered meaningful (McDonald et al., 2010;
Ramsay et al., 2011). Slow and tight binding inhibitors also
require special analysis (Morrison, 1969).
For irreversible inhibition, a time course of the development
of the inactive enzyme is essential. The best compounds for
specific irreversible inhibition in vivo are mechanism-based
inhibitors, making use of the catalytic specificity of the target
itself. However, sometimes even mechanism-based activation to
a reactive product can be catalyzed by more than one enzyme,
as seen for the MAO inhibitor tranylcypromine that irreversibly
modifies the flavin in MAO after single electron oxidation
(Silverman, 1983; Bonivento et al., 2010). Tranylcypromine
was recently found to modify also the flavin in the epigenetic
histone demethylase enzyme LSD1 (Schmidt and McCafferty,
2007; Binda et al., 2010). For medicinal chemistry screening,
irreversible inhibition can be detected as a decrease in the IC50
value after 30 min preincubation compared to no preincubation.
For example, for MAO B the IC50 for tranylcypromine without
preincubation is 4µMbut if preincubated with the enzyme for 30
min before substrate is added, the IC50 is 0.074 µM (Malcomson
et al., 2015). Proper characterization of mechanism-based
inactivation requires measurement of the rate of production of
inactive enzyme over time with several inhibitor concentrations
to obtain KI and kinact (Kitz and Wilson, 1962).
Catalysis consists of both binding and kinetics steps.
Theoretical screening measuring the sum of the optimal
interactions between a compound and a target addresses only
binding (and that with limitations depending on the restrictions
placed on molecular dynamics). As a result, enzyme IC50
values are frequently not in accord with computed binding
constants. Although Ki and KD can be numerically the same if
measurements are made in a simple Michaelis-Menten system,
they never have the same meaning. Nonetheless, theoretical
screening is a useful tool, particularly for large compound
libraries and to facilitate repurposing of existing drugs used for
other clinical targets (Hughes et al., 2016; Nikolic et al., 2016).
Cholinesterases (AchE, BchE)
AChE/BChE Location, Structure, Activity,
Redundancy
AChE is located at neuromuscular junctions and in the
central nervous system on the outside of the post-synaptic
cell membranes, mainly in a tetrameric form. A Ser-His-Glu
catalytic triad in the active site catalyzes the hydrolysis, and
anionic and hydrophobic groups in the peripheral anionic site
(PAS) contribute to binding a wide range of chemical structures
(Figure 1). The drug, donepezil, spans both sites with aromatic
stacking contributing to the nanomolar binding affinity, as shown
in the crystal structure of the human AChE (Cheung et al., 2012).
The PAS has a function in allosteric modulation of AChE activity
and in increasing amyloid (Inestrosa et al., 2008; Hou et al., 2014).
BChE may also have a role in amyloid plaque formation
(Darvesh et al., 2012). It is found mainly in plasma as a soluble
monomer secreted by glial cells (Greig et al., 2002). Although
the two enzymes share 65% homology and a similar hydrophobic
active site structure, they have different specificities in part due
to two aromatic residues (Phe295 and Phe297) that constrict the
20 Å long gorge in AChE (Greig et al., 2002; Nicolet et al., 2003).
The KM values and turnover numbers with acetylcholine are 0.1
mM and 6500 s−1 for AChE and 0.15 mM and 1433 s−1 for BChE
(http://www.brenda-enzymes.org). In the normal brain where
AChE is localize on the post synaptic membrane it was estimated
that 90% of acetylcholine hydrolysis is catalyzed by AChE (Greig
et al., 2002). However, BChE is plentiful and secreted by the glial
cells so that if AChE is inhibited or is defective as in AChE-knock-
out mice, the hydrolysis can be catalyzed by BChE (Mesulam
et al., 2002). Thus, in current efforts to design multitarget drugs,
reversible inhibition of both AChE and BChE is considered
desirable.
Cholinesterase Assay and Inhibitors
Both AChE and BChE can be assayed using acetylthiocholine, but
butyrylthiocholine is selective for BChE. The enzymes hydrolyse
acetylthiocholine to acetate and thiocholine. Thiocholine reacts
with Ellman’s reagent (DTNB) to form a mixed dithiol,
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FIGURE 1 | Ligand binding cavities of (A) AChE and (B) BChE. AChE (shown in orange) is in complex with donepezil (shown in CPK colored sticks with carbons
in green, PDB ID: 4EY7), while BChE (shown metal blue) is in complex with choline (shown in CPK colored sticks with carbons in light blue, PDB ID: 1P0M). The top
panels show the cartoon representations with detail in sticks of relevant residues involved at the gorge entrances, the PAS regions or the catalytic triads (labeled in red),
as well as the omega loops colored in yellow. Middle and lower panels show top and lateral views of the ligand binding cavities. The entrance loops are highlighted in
pink and yellow respectively. PDB files were obtained from the protein databank and figures were produced using the PyMol software (PyMOL, http://www.pymol.org).
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liberating 5-thio-2-nitrobenzoate that absorbs at 412 nm. The
molar absorption coefficient is 14,150M−1 cm−1; (Riddles et al.,
1979) but it can vary slightly with salt concentration, pH, and
temperature (Ellman et al., 1961; Eyer et al., 2003). The KM for
acetylthiocholine (0.025–0.05mM) is similar for both enzymes
although the rate with BChE is slower.
Common drugs inhibiting AChE and BChE are donepezil and
tacrine (see Table 1) (Camps et al., 2008; Esteban et al., 2014;
Wang L. et al., 2014). Carbamates are also reversible inhibitors
(e.g., rivastigmine), coumarins, and several natural compounds
have also been investigated. Harmine, an endogenous compound
from the breakdown of tryptophan is also an inhibitor (He et al.,
2015). In the last 5 years most inhibitor development has focused
onmaintaining a relatively equal inhibitory activity against AChE
and BChE with IC50 values below µmolar concentrations in a
compound that also acts on other targets such as MAO (see
below), antioxidant, metal chelation, and preventing protein
aggregation (for reviews see: León et al., 2013; Swomley and
Butterfield, 2015). Many groups have synthesized and tested a
variety of combinations. Here, we consider in detail ASS234, an
example from our own work. ASS234 (Table 1) with potency
similar to tacrine is almost equipotent on human AChE and
BChE. ASS234 also has antioxidant properties, inhibits Aβ
aggregation, and decreases Aβ-induced apoptosis in cellular
studies (Bolea et al., 2013).
The discovery of compounds that combine cholinesterase
inhibition with binding to other targets of interest for AD is
also underway. For example, the serotonin receptor, 5-HT4, has
been linked to memory deficits (Cho and Hu, 2007; Lezoualc’h,
2007; Russo et al., 2009). Stimulation causes release of ACh
and increases dopamine, serotonin, and γ-aminobutyric acid
(GABA) release, and thus could act synergistically with ChE
and MAO inhibition. 5-HT4 stimulation also increases the safer
non-amyloidogenic pathway for APP cleavage (Cochet et al.,
2013). Agonists or partial agonists have been designed and the
first MTDLs with cholinesterase and receptor binding have been
designed (Lecoutey et al., 2014; Rochais et al., 2015).
Monoamine Oxidases (MAO A, MAO B)
Neurotransmitter levels influence brain activity and preventing
neurotransmitter breakdown has an anti-depressant effect. The
monoamines are catabolized by MAO and COMT, inhibitors
for which are useful in PD (Talati et al., 2009). Mice treated
with MAOI showed significantly higher noradrenaline and
serotonin levels in brain and significantly lower metabolites
(including DOPAC from dopamine) (Lum and Stahl, 2012).
Higher monoamine levels as a result of MAOI are also seen
in rats in micro-dialysis experiments (Bazzu et al., 2013; Bolea
et al., 2014), and in humans are observed as serotonin toxicity in
patients given non-selective MAOI on top of serotonin reuptake
inhibitors (SSRIs) (Gillman, 2011). Changes inmonoamine levels
also have downstream effects on expression and function of
receptors and other proteins (Finberg, 2014).
TABLE 1 | AChE and MAO inhibitors and the inhibitory activity of MTDL.
Structure Compound AChE (µM) BChE (µM) MAO A (nM) MAO B (nM) References
Tacrine 0.2051 0.0441 – – 1Camps et al., 2008
Donepezil 0.0121
0.0112
7.31
6.222
8500003
Rat
150003
Rat
1Camps et al., 2008;
2Esteban et al., 2014;
3Wang L. et al., 2014
PF1901N >1002 >1002 7902 112 2Esteban et al., 2014
ASS234 0.354
Eel
0.812
0.464
Eel
1.822
5.244
0.172
433504
158302
2Esteban et al., 2014;
4Bolea et al., 2011
Clorgyline – – 0.422 106602 2Esteban et al., 2014
L-Deprenyl – – 6302 3.02 2Esteban et al., 2014
Enzymes activities were measured after 30 min incubation with the inhibitor; inhibition is for the human enzyme unless specified (marked in italics). The – indicates no inhibition.
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Altered MAO levels are associated with brain pathology.
MAOA/B knockout mice displaying anxiety-like symptoms have
greatly elevated monoamine levels (Chen et al., 2004). MAO B,
located mainly in glial cells, increases with age and is elevated in
AD and PD (Kennedy et al., 2003; Zellner et al., 2012; Woodard
et al., 2014; Ooi et al., 2015). Inhibition of MAO B by compounds
in cigarette smoke is associated with delayed onset of PD, and the
MAO B inhibitor, deprenyl, delays the need to begin levodopa
treatment in PD patients. Considering genetic variations, the A
allele of the common A644G single nucleotide polymorphism
in intron 13 of the MAO B gene is associated with slightly
lower platelet MAO B activity and slightly less risk of PD (Liu
et al., 2014). For MAO A, a low activity allele is associated with
aggression (Gallardo-Pujol et al., 2013), and the high activity that
results from the long repeat allele in the promotor region of the
gene is associated with depression (Meyer et al., 2006), although
a Positron Emission Tomography study found no significant
difference in activity MAOA activity in the human brain (Fowler
et al., 2015). Inhibition of MAO A has also been shown to
decrease the oxidative stress that can result from the hydrogen
peroxide and the aldehyde products of MAO catalysis both in
heart and brain (Kaludercic et al., 2011; Ooi et al., 2015).
MAO A and MAO B Structure, Activity, Redundancy
MAO A and B share 70% homology and very similar active sites
(reviewed in Edmondson et al., 2007). A major influence on
substrate and inhibitor specificity is the narrow part (“gate”) of
theMAOB cavity defined by I199 and Y326 (Figure 2). However,
the design of selective inhibitors is not simple, although in general
MAO A can accommodate bulkier compounds. Simply changing
one substituent can alter affinity for one form but not the other.
For example, adding a second carbonitrile group to a small furan
scaffold, increased the affinity for MAO A by 10-fold but not for
MAO B (Juárez-Jiménez et al., 2014) due to a hydrogen bond
to asparagine 181 in MAO A. At that position (172 in MAO B)
MAO B has a cysteine residue that can contribute to MAO B-
selective binding. Structure-function analyses for the design of
selective MAO inhibitors has been reviewed recently (Vilar et al.,
2012; Patil et al., 2013; Carradori and Petzer, 2015).
Since MAO A and B are located on the X chromosome,
human MAO deficiencies were first discovered in males. MAO
A deficiency is associated with aggression, but MAO B deficient
subjects were mentally normal. The combined deletion found
in Norrie disease is associated with severe mental retardation
(Brunner et al., 1993; Lenders et al., 1996). Detailed examination
of the effects of deletions are now possible through knock-
out mice, studies that provide insight into the roles of MAO
in behavior and development (Shih and Chen, 1999; Bortolato
and Shih, 2011). In mice, as in humans, MAO A deficiency
is associated with aggression. MAO B deficiency does not
perturb monoamine metabolism to any great extent but results
in excretion of higher amounts of phenylethylamine. The
substrate specificities of the two forms overlap, with MAO A
metabolizing serotonin well, MAO B PEA, but both dopamine
and noradrenaline. The relative efficiency of catalysis by the
two forms is best expressed by the maximum catalytic velocity
divided by the KM, values; these can be found in (Youdim
FIGURE 2 | MAO active site cavities showing the FAD cofactor and the
ligand in the crystal structures. (A) MAO A in complex with clorgyline (PDB
ID: 2BXS) and (B) MAO B in complex with deprenyl (PDB ID: 2BYB). The FAD
cofactors inside the cavities are shown in CPK colored sticks with carbons in
pink, the clorgyline and deprenyl ligands are also shown in sticks with carbons
in blue, and key residues around the ligand cavity are shown in CPK colored
sticks with carbons in orange and metal blue for MAO A and MAO B,
respectively. The entrance loops are highlighted in pink and yellow respectively.
The PDB files were obtained from the protein databank and figures were
produced using PyMOL (http://www.pymol.org).
et al., 2006). In contrast to acetylcholine neurotransmission, the
primary termination of the monoamine chemical signal is by
reuptake of the monoamines, first into the neuron and then back
into the storage vesicles. Inhibition of MAO increases stores of
monoamines, for example in PD where inhibition of MAO B
slows the breakdown of dopamine (Finberg, 2014).
MAO A/B Assay and Inhibitors
MAO can be assayed using absorbance or fluorescence changes,
by radiolabeled product detection, by HPLC separation of the
product, or by coupling the second product H2O2 to a detection
system. The simplest assay is the measurement of the oxidation
of kynuramine either continuously by the absorbance change at
314 nm (Weissbach et al., 1960) or in a stopped assay by the
fluorescence of the product.
Recombinant human MAO A and MAO B expressed in
insect cell membranes is now commercially available but the
low activity requires the sensitive coupled assay where H2O2 is
used by horseradish peroxidase to convert the non-fluorescent
dye, N-acetyl-3,7-dihydroxyphenoxazine (Amplex Red), to the
fluorescent resorufin (Zhou et al., 1997). As with all coupled
assays, considerable caremust be taken to check the validity of the
assay by ensuring that the enzyme of interest (MAO in this case)
is rate limiting. Inhibitors can quench or enhance fluorescence,
or may inhibit horseradish peroxidase. These interfering factors
must be checked for each type of inhibitor. It should be noted that
Amplex Red, N-acetyl-3,7-dihydroxyphenoxazine, a structure
similar to the MAO A inhibitor Methylene Blue (Ramsay et al.,
2007; Milczek et al., 2011) inhibits MAO A so the dye must
be used at 20–50 µM, and not the 200 µM recommend by the
assay kit manufacturer. Most substrates (except dopamine) can
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be used in this continuous coupled assay. The most frequently
used is tyramine which has a KM of 127 µM with MAO A
and 107 µM with MAO B (Youdim et al., 2006). However,
different laboratories report various values, so the KM should be
checked for each condition used.The discovery of highly selective
reversible inhibitors for MAO A or MAO B has been the focus
of compound synthesis for antidepressant design in recent years
due to reduced side effects and lower drug-drug/food interaction
risk. Some effective reversible inhibitors are harmine (K i = 5
nM) (Kim et al., 1997) used to measure MAO A occupancy
in positron emission tomography scans (Sacher et al., 2011)
and moclobemide (used in anxiety disorders). Moclobemide,
giving 70–78% occupancy of MAO A at clinically effective doses
(Sacher et al., 2011), is useful because, as a reversible inhibitor,
it does not inactivate the MAO A in the gut wall and so does
not potentiate the vascular effects due to tyramine from the
intestine. For MAO B, safinamide (K i = 0.5 µM) (Binda et al.,
2007) is in clinical trials for adjunct therapy in PD (Finberg,
2014). Traditional medicinal chemistry approaches, screening of
compound libraries, and computational screening continue the
search for new scaffolds for reversible inhibitors (Santana et al.,
2006; Shelke et al., 2011).
However, irreversible inhibition and the slow turnover rate
of MAO allows lower doses compared to reversible inhibitors
and thus lower risk of side effects. All the common MAOI
used clinically for depression and for PD are irreversible
inhibitors (Table 1). The mechanism-based inactivation of MAO
can be achieved by phenylzines, cyclopropopylamines, and
propynamines. The selective irreversible inhibitors clorgyline for
MAO A and deprenyl for MAO B both contain the propargyl
moiety that after oxidation by MAO A forms a covalent adduct
with the N5 of the FAD cofactor (Binda et al., 2002; De Colibus
et al., 2005). The propargyl moiety is a useful small entity to add
MAOI capability to molecules designed for other targets to give
MTDL as describe below. The propargyl group must be oxidized
by MAO to generate the reactive species that forms the covalent
bond with the enzyme. The rate of inactivation by propargyl
compounds for both MAO A and MAO B is around 0.2 min−1
with selectivity coming from the binding (Esteban et al., 2014;
Malcomson et al., 2015). A further benefit of the propargyl moiety
is its association with neuroprotection at levels lower than for
inhibition of MAO (Naoi and Maruyama, 2010; Weinreb et al.,
2011).
In assessing inhibitors of MAO, a final word of caution
must be included regarding the considerable species differences
that have been noted for inhibitor binding (Krueger et al.,
1995). Happily, the human and rat sensitivities to MAOI are
fairly similar but there are clear structural active site differences
between the rat and human MAOs (Upadhyay et al., 2008) with
implications for drug design (Novaroli et al., 2006; Fierro et al.,
2007).
Multi-Target Designed Ligands (MTDL)
That Inhibit ChEs and MAOs
One promising MTDL investigated under the auspices of COST
Action CM1103 is ASS234 (N-((5-(3-(1-benzylpiperidin-4-
yl)propoxy)-1-methyl-1H-indol-2-yl)methyl)-N-methylprop-2-
yn-1-amine). The indole group aids MAO A selectivity and
the propynamine (propargyl) group allows for irreversible
inhibition. However, by adding a 1-benzylpiperidine fragment
(similar to the AChE inhibitor, donepezil), this compound
becomes also a reversible inhibitor for AChE and BChE (Bolea
et al., 2011). During biological assessment, it became apparent
that this compound has neuroprotective properties, by inhibiting
Aβ42 and Aβ40 self-aggregation into plaques, and by protecting
against depletion of antioxidative enzymes (Bolea et al.,
2013). Therefore ASS234 has been patented (PCT/ES070186;
WO2011/113988 A1) as a promising compound for the
treatment of AD.Many other ChE/MAO targeted MTDL
have been designed in the last 5 years, either propargyl-based
(Youdim, 2013; Bautista-Aguilera et al., 2014b; Samadi et al.,
2015; Weinreb et al., 2015) or coumarins derivatives (Pisani
et al., 2011; Patil et al., 2013; Farina et al., 2015; Xie et al., 2015).
The challenge will be to add further neuroprotective properties
to progress to a disease-modifying drug.
MITOCHONDRIAL HOMEOSTASIS AND
APOPTOSIS
Mitochondrial Fusion, Fission, and
Trafficking
Mitochondria are dynamic organelles with the ability to
divide (fission) and fuse (fusion) as well as to concentrate in
particular subcellular locations. Regulation of these processes
is crucial for cell health and apoptosis (Hales, 2004, 2010).
Fission and fusion play critical roles in maintaining functional
mitochondria when cells experience metabolic or environmental
stresses, a reason why their improper regulation associates with
several human genetic neurodegenerative diseases affecting to
neuronal survival and plasticity (Hales, 2010; Youle and van
der Bliek, 2012). Fusion is proposed to mitigate stress allowing
complementation by mixing contents of partially damaged
mitochondria. Fission, besides being required in the creation
of new mitochondria, also contributes to quality control by
facilitating both removal of damaged mitochondria (mitophagy)
and apoptosis under cellular stress situations (Lee et al.,
2004). The combined action of several GTPases contributes to
the dynamic mitochondrial networks; Drp1/Dnm1 is key in
mitochondrial division, mitofusins (Mfn1 and Mfn2) control
outer mitochondrial membrane fusion, andOPA1mediates inner
mitochondrial membrane fusion (Griparic et al., 2004, 2007;
Ishihara et al., 2006; Cohen et al., 2008). Neurons are more
sensitive than other cells to mutations in the genes coding
for these proteins, indicating the importance of mitochondrial
dynamics for the maintenance of the nervous system integrity
(Mandemakers et al., 2007). Deletion of either of the two
mitofusins results in unbalanced fission and mitochondrial
fragmentation (Koshiba et al., 2004). Mutations in Mfn2
cause the Charcot-Marie-Tooth disease (Züchner et al., 2004),
and mutations in OPA1 are associated with genetic forms
of blindness (Delettre et al., 2000) (Figure 3). A number of
other factors contribute to modulate these GTPases activities
and changes in their molecular shapes precisely control these
processes (Mandemakers et al., 2007). For example, several brain
neurodegenerative disorders cause decrease inmitochondrial size
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FIGURE 3 | Schematic representation of mitochondrial dynamics. Steady state mitochondrial morphology requires a balance of fission and fusion events.
During organelle fission Drp1 is recruited from the cytosol to the outer mitochondrial membrane, where it interacts directly or indirectly with Fis1 forming high molecular
weight oligomers on the mitochondrial surface. This leads to constriction of mitochondria and sequential separation of the inner and outer membrane. Once Drp1 is
released fission is complete. Fission also allows isolation for mitochondria that cannot be repaired followed by degradation through mitophagy, and is also important
for subcellular distribution and transportation of mitochondria based on local energy needs. Mitochondrial fusion is a two-step process that requires outer and inner
membrane fusion. Outer membrane fusion is facilitated by mitofusins tethering of adjacent membranes. This is subsequently followed by inner membrane fusion,
which is GTP dependent and regulated by OPA1. Fusion allows for functional complementation and repair of damaged mitochondria.
and increased Drp1 translocation to mitochondria, increasing
fission events. Treatments inhibiting Drp1 have been shown
to restore mitochondrial length, reduce loss of new-born
hippocampal neurons, and improve hippocampal-dependent
learning and memory after damage (Li et al., 2015; Fischer et al.,
2016). Therefore, reducing mitochondrial fission may contribute
to rescue from brain injury, and the possibility to regulate the
mechanisms of fusion and fission by different mediators in
different tissues can represent a potential therapeutic target for
related disorders.
Due to their complex structural and molecular features,
neurons also require mechanisms for mitochondria trafficking
to their distal destinations (presynaptic bouton, axons, synaptic
terminals) and anchoring in regions where metabolism is in
high demand. Failure to deliver a functional mitochondrion
to the appropriate site within a neuron could contribute to
neuronal dysfunction. Besides mitochondrial dynamics, the
proteins mentioned above are also involved in mitochondrial
subcellular positioning in neurons, ensuring a relatively constant
mitochondrial population. As an example, membrane bound
OPA1 influences mitochondrial elongation and transport in
a Mfn1 dependent manner, while its soluble form regulates
the tightness of mitochondrial cristae junctions and, therefore,
release of apoptotic factors (Frezza et al., 2006) as well as
cristae shape, which in turn, conditions supercomplex assembly
(Cogliati et al., 2013). Mitochondria trafficking and anchoring
mechanisms also rely on molecular motors (as KIF5 and dynein
motors) which recruit mitochondria into stationary pools
(Rintoul and Reynolds, 2010; Sheng and Cai, 2012; Sheng, 2014),
and ensure neuronal mitochondria are adequately distributed
where constant energy supply is crucial. Malfunctioning
mitochondria are removed by mitophagy to minimize oxidative
damage to the cell, with neurons again facing the challenge of
their mitochondria being involved in distal processes located
far from the cell body where lysosomes are abundant. The
presence of functional lysosomes in axons has been evidenced
to contribute to mitophagy of damaged mitochondria, and the
local PINK1–Parkin-mediated mitophagy pathway provides
rapid neuroprotection against oxidative stress without a
requirement for retrograde transport to the soma (Ashrafi et al.,
2014).
An imbalance of these processes involved in mitochondria
dynamics and homeostasis (fission, fusion, trafficking, and
mitophagy) can be detrimental to mitochondrial function,
causing decreased respiration, ROS production, and apoptosis.
All these are also symptoms caused by a traumatic brain
injury, further indicating a prominent role of mitochondria in
neuropathophysiology.
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Mutations in Mitochondrial Proteins
Mutations in other proteins with primary mitochondrial
localization that cause abnormalities of protein conformation
(mis-folding or aggregation) also result in neurodegenerative
disorders. Examples include the kinase PANK2 involved
in coenzyme A biosynthesis and degradation of some
neurotransmitters, frataxin implicated in iron metabolism,
PINK1 critical to prevent oxidative stress, or pitrilysin
metallopeptidase which digests oligopeptides, including the
mitochondrial fraction of amyloid-beta (Mandemakers et al.,
2007; Brunetti et al., 2015). In addition, mutations in some
non-mitochondrial proteins appear to affect mitochondrial
function in neurodegeneration (such as superoxide dismutase 1,
Parkin, α-synuclein, MAO or the kinase LRRK2), although in
general the role of most of these proteins in neurodegeneration
must still be elucidated (Nakamura et al., 2011; Schapira and
Gegg, 2011; Haddad and Nakamura, 2015).
Apoptosis
Apoptosis is a common type of cell death in neurodegenerative
diseases, in which mitochondria make a major contribution to
initiation of the death cascade (Petit et al., 1996; Naoi et al.,
2006). Fission and fusion rates precisely regulate the number
and morphology of mitochondria within a cell, with network
fragmentation and cristae remodeling occurring during the early
stages of apoptotic cell death (Wang and Youle, 2009; Youle
and van der Bliek, 2012). In this context it is not surprising
that proteins involved in mitochondrial morphology control also
participate in apoptosis, and proteins associated with apoptosis
regulation affect mitochondrial ultrastructure. Key apoptotic
events in mitochondria include the release of caspase-dependent
activators (cytochrome c) and caspase-independent apoptotic
factors (the flavoenzyme apoptosis inducing factor, AIF), changes
in electron transport, loss of mitochondrial transmembrane
potential, altered cellular oxidation-reduction, and participation
of pro- and anti- apoptotic Bcl-2 family proteins (Saraste and
Pulkki, 2000; Edinger and Thompson, 2004). The different signals
that converge on mitochondria to trigger or inhibit these events
and their downstream effects delineate several major pathways in
cell death (Wang and Youle, 2009).
As an example, AIF is an apoptotic factor that when released
from the mitochondria and translocated to nucleus induces
chromatin condensation and DNA fragmentation, while also
having a vital role inmitochondria healthy cells (Susin et al., 1999;
Miramar et al., 2001). Complex I (CI) dysfunction has long been
associated with PD. AIF deficiency produces reduced levels of
CI subunits, decreased CI activity, and impaired CI-dependent
mitochondrial respiration (Vahsen et al., 2004; Urbano et al.,
2005; Cheung et al., 2006). Although these AIF linked CI
structural alterations have not been shown to cause dopaminergic
neurodegeneration, an increase is the susceptibility of these
neurons to exogenous PD neurotoxins has been proven (Perier
et al., 2010, 2012). The exact role of AIF in intermembrane space
of mitochondria of healthy cells has remained a conundrum, but
several interesting novelties have been presented in the recent
years regarding its redox activity in this organelle (Sevrioukova,
2009, 2011; Ferreira et al., 2014; Villanueva et al., 2015). Recently,
it has also been described that the physical and functional
NADH-dependent interaction between AIF and the protein
CHCHD4 regulates the correct assembly and maintenance of the
respiratory chain complexes (Hangen et al., 2015; Meyer et al.,
2015). CHCHD4 participates in mitochondrial protein import
and catalyzes oxidative protein folding in cooperation with the
sulfhydryl oxidase GFER/ALR/Erv1p (Chacinska et al., 2008;
Banci et al., 2009; Fischer et al., 2013; Koch and Schmid, 2014).
Upon interaction with NADH, AIF undergoes reduction, with
the concomitant dimerization and formation of highly stable
charge transfer complexes. Both AIF dimers and charge transfer
complexes are proposed to have a physiological function in a
model where AIF would act as a sensor of the mitochondrial
redox state (Churbanova and Sevrioukova, 2008; Ferreira et al.,
2014; Sorrentino et al., 2015). In addition to the interplay with
CHCHD4, AIF might also interact at the mitochondria with
other proteins yet to be discovered.
Neurons are the cells that suffer larger effects upon deficiency
of AIF, probably due to their high energetic dependency on
the mitochondrial OXPHOS metabolism. In addition to AIF
deficiency being related to different neurodegeneration types
(Klein et al., 2002; Joza et al., 2005; van Empel et al., 2005; Cheung
et al., 2006; Ishimura et al., 2008), six AIF pathological mutations
have also been reported to produce human neurodegenerative
diseases, with all patients with AIF mutations showing muscular
atrophy, neuropathy and ataxia (Ghezzi et al., 2010; Berger
et al., 2011; Rinaldi et al., 2012; Ardissone et al., 2015; Diodato
et al., 2015; Kettwig et al., 2015). Thus, AIF appears as an
essential protein for post-mitotic neuron survival, cerebellar
development, and therefore, neurogenesis (Ishimura et al., 2008).
AIF is also one of the proteins described to associate with OPA1
to cooperatively regulate and stabilize the respiratory chain,
this interaction being proposed as one of the factors defining
mitochondrial morphology (Cheung et al., 2006; Zanna et al.,
2008).
The present therapeutics for neurodegenerative diseases
are in general symptomatic and lack neuroprotective and
neurorestorative properties, being not able to delay disease or
modify its neuronal activity. In recent years, the development
of multi-target neuroprotective and neurorestorative drugs
with simultaneous action on enzymes such as cholinesterase,
BChE and MAO A/B activities or being able to enhance the
action of proteins intimately associated with mitochondrial
biogenesis (Youdim, 2013; Youdim and Oh, 2013). A potential
addition for this therapeutic strategy in neurodegenerative
diseases is to halt common and progressive pathways for
neural injury and cell death. In the current development
of neuroprotective drugs, mitochondria are a key target
to protect against cell death by preventing mitochondrial
permeabilization, Ca2+ efflux, membrane potential decline and
release of apoptotic factors while also inducing anti-apoptotic
pro-survival proteins (Naoi et al., 2007; Weinreb et al., 2012,
2016, 2015). Connections between morphological regulation
and the bioenergetics status of mitochondria are reciprocally
responsive processes (Figure 4), with functional abnormality
invoking morphological alterations in many human diseases and
genetic defects in mitochondrial fusion/fission genes or insults
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FIGURE 4 | Schematic representation of the timeline of mitochondrial bioenergetics and morphological changes inducing pathologies. Electrons
leaking from the electron transport chain generate ROS, which damage mitochondrial membrane, mitochondrial DNA, and proteins. Neurons have limited defense
against oxidative damage and are highly vulnerable to ROS. Damaged/depolarized mitochondria release cytochrome c that triggers cell death by activating caspases
as well as AIF that initiates apoptosis in a caspase independent manner.
inducing mitochondrial deformation (accompanied by oxidative
stress and/or apoptosis) causing human diseases of lethal
consequence (Galloway et al., 2012, 2014; Westermann, 2012).
In this context, controlling the mitochondrial morphology by
manipulating fission and fusion emerges as a future therapeutic
strategy to decrease the pathological outcome.
ANTIOXIDANT PROPERTIES IN AN
EXAMPLE MTDL
Antioxidant properties, part of a desired pharmacologic profile
for MTDLs designed to treat neurodegeneration, are screened
by various in silico, in vitro and in vivo methods. Arising
from the structure of the parent antioxidant drug stobadine
(Horáková et al., 1994; Horáková and Stolc, 1998), several
dozen derivatives with a hexahydropyridoindolic scaffold were
synthesized and tested for their antioxidant and neuroprotective
effect (Rackova et al., 2006; Stolc et al., 2006, 2010; Juranek et al.,
2010). The aim of the new design was to use a wide knowledge
of the pharmacological actions of stobadine to develop new
substances with even higher antioxidant activity and reduced
side effects. The screening confirmed the enhancement of
the intrinsic radical scavenging activity of the 8-methoxy
substituted derivatives, which was predicted for the right
position of the electron-donating methoxy group. Several
alkoxy-carbonyl substituents at the N2 position were tested
to find sufficiently high lipophilicity and lower basicity of
the molecule. From the compounds synthesized and tested
(±)-cis-8-methoxy-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-
b]indole-2-carboxylic acid ethyl ester (SMe1EC2, Figure 5),
which showed enhanced antioxidant properties near a lipophilic
phase, was chosen for a detailed study.
SMe1EC2 had high intrinsic scavenging activity as measured
with 1,1TM-diphenyl-2-picrylhydrazyl (DPPH) (Stefek et al.,
2013). The initial velocity of DPPH decolorization by 50
µM SMe1EC2 (0.507 ± 0.003 optical density(OD)/min)
was comparable with that of equimolar trolox (0.494 ±
0.009 OD/min). The parent compound stobadine at 50 µM
concentration was about three times less efficient (0.156 ±
0.019 OD/min). The high intrinsic activity together with
enhanced lipophilicity resulted in significantly higher antioxidant
properties in rat brain homogenate or in a cellular model (red
cells, macrophage RAW 264.7 cell cultures) when compared
with stobadine (Stolc et al., 2006; Stefek et al., 2013; Balcerczyk
et al., 2014). In the experiment with red blood cells two types
of initiators of the haemolysis were used: hydrophilic AAPH
(2,2′-azobis(2-amidinopropane) hydrochloride) and lipophilic
t-BuOOH. While the activity of more hydrophilic and basic
stobadine surpassed that of SMe1EC2 in AAPH induced
haemolysis, SMe1EC2 exceeded stobadine in red blood cells
protection when lipophilic t-BuOOH was used (Stefek et al.,
2013).
On a tissue level SMe1EC2 was able to recover the field action
potential amplitude in CA1 region of rat hippocampal slices after
20 min reoxygenation following 6 min hypoxia to control value
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FIGURE 5 | Compound SMe1EC2 compared with the parent drug stobadine according to the structural, and in vitro and in vivo properties.
(100%) at a concentration of 3µmol/l (Stolc et al., 2006). The field
action potential, created by the pyramidal neurons in the CA1
region after electric stimulation of Schäffer collaterals in the CA3
region and involving excitation of glutamatergic synapses, is an
appropriate model for functional status of brain. Neuroprotective
effects of the compound were shown also in rat hippocampal
slices attacked by Fe2+/ascorbic acid system (Gáspárová et al.,
2010). Simultaneously, SMe1EC2 improved functional deficits
and edema formation in rat hippocampus exposed to ischemia ex
vivo after several days of oral treatment of rats (Gáspárová et al.,
2009).
In order to estimate the in vivo neuroprotective potential of
these new hexahydropyridoindoles, an experiment with acute
head trauma model in mice has been performed (Stolc et al.,
2006, 2010, 2011). There is a close relation between a traumatic
head injury and a risk for later development of PD (Witcher
et al., 2015; Xu et al., 2015). People aged 55 years and older who
were treated in the hospital for traumatic brain injury were 44%
more likely to develop PD over the next six years than those
who sustained injuries, but not head injuries (Gardner et al.,
2015). In the framework of the murine head trauma experiment
the drugs were administered i.v. immediately after the trauma
in single doses equimolar to 1mg of stobadine dihydrochloride,
and 1 h later the total sensomotoric score was monitored.
SMe1EC2 proved to be excellent compound in improvement of
a total sensomotoric score (Stolc et al., 2006, 2011), achieving the
value 244.33 ± 50.20% (p = 0.0036 comparing to placebo) and
exceeding such compounds as melatonin, stobadine and SPBN
(2-sulfo-α-phenyl-N-tert-butyl-nitrone). During this experiment
brain oedema was also evaluated by brain wet weight assessment
and brain histology. After triple i.v. administration of 1.14mg/kg
of SMe1EC2 in 1min, 2 h and 24 h after Acute Head Trauma,
the increase in brain wet weight induced by the trauma and
culminating 5 h after the insult was significantly diminished
almost to the control level. The reduction of the oedema,
occurring especially in glial cells, was also proved histologically.
Moreover, the occurrence of subdural bleeding, meningeal
bleeding and bleeding in brain chambers throughout the whole
follow-up period (168 h) was significantly reduced.
The compound was also tested for cell protection properties
in the framework of diabetes-related pathological processes. AD
and type 2 diabetes mellitus present many common features
(de la Monte and Wands, 2008; Correia et al., 2012c; Ahmad,
2013). Both diseases are connected with malfunctions in glucose
metabolism and mitochondria, elevated oxidative stress and
activation of pro-inflammatory cytokines. SMe1EC2 enhanced
the viability of cultured HT22 neuronal cells exposed to high
glucose with simultaneous attenuating of parameters of the
oxidations stress (Rackova et al., 2009). The compound also
protected rat pancreatic INS-1E β cell cultures against cytotoxic
effects of hydrogen peroxide and inhibited profoundly the time-
delayed apoptotic changes induced by the attack (Racˇková et al.,
2011).
Besides metabolic disorders related to the high glucose plasma
levels, pathologies connected with a high fat diet may also
be related to neurodegeneration process (Morris et al., 2010).
SMe1EC2 showed also efficiency in treating metabolic high-fat
related disorders. In the rat model of hypertriglyceridemia it was
shown that higher intake of cholesterol induced an increase in
the number of active Na+/ K+-ATPase molecules in HTG rats,
which resulted in the increased retention of sodium. A three-
week treatment of animals kept on high cholesterol diet with
SMe1EC2 in a dose of 10mg kg−1 day−1 normalized the function
of renal Na+/, K+-ATPase to the level comparable in HTG rats
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fed with the standard diet. For a comparison, fenofibrate in a
dose of 100mg kg−1 day−1 reversed the function of renal Na+/
K+-ATPase only slightly (Mézešová et al., 2012).
Further significant property of SMe1EC2 was its ability to
protect endothelium under conditions of experimental diabetes
of rats. It significantly decreased endothelaemia of diabetic rats
and improved endothelium-dependent relaxation of arteries,
slightly decreased ROS-production and increased bioavailability
of nitric oxide in the aorta (Sotníková et al., 2011). Overall,
the compound attenuated endothelial injury in diabetic animals.
Although mechanism of this effect is still not clear, it could
represent further positive effect in MTDL potential for treatment
of neurodegenerative diseases.
Four ethological tests with rats (open field, elevated plus-
maze, light/dark box exploration, forced swim test) were used to
obtain information about anxiolytic and antidepressant activity
of SMe1EC2 (Sedlácˇková et al., 2011). The substance was
administered intraperitoneally 30min before the tests at doses
of 1, 10, and 25mg/kg. SMe1EC2 was found to exert anxiolytic
activity in elevated plus maze with no affection of locomotor
activity in a dose-dependent manner. The middle dose of
SMe1EC2 resulted in similar anti-anxiety effect manifested in rats
as that of diazepam (dose 2.5mg/kg). A medium anti-depressant
activity was also predicted by combinatorial in silico methods
(Majekova et al., 2013).
The acute toxicity of SMe1EC2 was assessed in mice after p.o.
and i.v. administration. For p.o., it was estimated in GHS scale
as 5, a compound with “comparatively low acute toxicity,” with
the LD50 value over 2000 mg/kg. After i.v. administration, the
LD50 of SMe1EC2 was 181.13 mg/kg (Stolc et al., 2006). The
results of prenatal developmental toxicity study were similar: the
compound demonstrated neither embryotoxic nor teratogenic
effects on rat fetuses and no signs of maternal toxicity were found
(Ujhazy et al., 2008).
Compound SMe1EC2 has been revealed to be a potential
multi-target drug for neuronal diseases. Apart from its good
distribution properties and high intrinsic radical scavenging
activity, this is supported by the results of in vivo experiments
on protection in the process of head trauma and diabetic damage
of endothelium.
CYTOCHROME P450
The cytochrome P450 (CYP) family is involved in different
steps of therapy from drug efficacy and dose requirement to
adverse drug reactions and direct toxicity (Zanger and Schwab,
2013). There are 18 mammalian CYP isoenzymes, which encode
57 genes in the human genome (Nebert et al., 2013). Of
these CYP isoenzymes, more than 10 belong to the CYP1,
2, and 3 families and are responsible for the metabolism of
more than 80% of xenobiotics and drugs used in therapy.
This indicates that the CYP-dependent metabolism is one of
the main factors in the regulation of drug concentration at a
target level (pharmacokinetic effects) and is indeed involved in
the adverse reactions of therapeutic compounds, in drug-drug
interaction and their toxic effect. The low substrate specificity
characterizing the CYP metabolism, is associated with the
evidence of a large genetic polymorphism of some isoforms,
particularly those involved in drug metabolism (i.e., CPY1A2,
2C9, 2C19, 2D6, and 3A4). Multi-allelic genetic polymorphisms,
which remarkably depend on ethnicity, (Preissner et al., 2013)
lead to distinct pharmacogenetic phenotypes termed as poor,
extensive, and ultrarapid metabolizers. The loss of function
promotes a reduced clearance with a consequent increase of
plasma concentrations, while the gain of function leads to
increased clearance and lower drug concentrations, resulting
in increase and decrease effect of the drug, respectively,
and potentially drug-related toxicity. These effects are not
only related to genetic polymorphisms, but CYPs activity
is regulated by chemicals and endogenous factors that can
be promoted either by the induction or inhibition of some
CYP activity. In the liver, most of the xenobiotic-metabolising
CYPs are inducible, but one exception is CYP2D6. In
general, control of protein expression can be exerted at the
transcriptional mRNA, translational and posttranslational level.
Posttranslational regulation has been described for CYP1A1,
CYP1A2, CYP2E1 and CYP3A4 (Werlinder et al., 2001;
Ingelman-Sundberg, 2004; Oesch-Bartlomowicz and Oesch,
2005; Smutny et al., 2013).
Pharmacoepigenomics is a new topic of research in the
regulation of xenobiotic metabolizing enzymes. Up to now
different studies indicate that DNA methylation and the
numerous combinations of post-translational modifications of
the histone proteins, are implicated in influencing the expression
of genes whose products are engaged in drug metabolism. In
addition, the increasing importance of the short regulatory
miRNAs, has to be emphasized and initial studies show their
involvement in regulating the expression of drug-metabolizing
enzymes (Tsuchiya et al., 2006; Pan et al., 2009; Ingelman-
Sundberg and Gomez, 2010).
Therefore, pharmacoepigenomics represents the future of
research on drug metabolism, while the molecular mechanism
of the transcriptional regulation of CYPs has been established
and consolidated in several studies. Transcriptional control is
of the highest importance and cytosolic receptors sensitive to
the concentration of the environmental xenobiotics are crucial,
namely the aryl hydrocarbon receptor (AhR), constitutive
androgen receptor (CAR), the pregnane X-receptor (PXR),
and peroxisome proliferator-activated receptor (PPARα). They
regulate CYP forms as follows: CYP1A1, CYP1A2 and CYP2S1
(AhR), CYP2C9, CYP3A4 (PXR), CYP2B6, CYP2C9, CYP3A4
(CAR), and CYP4A family (PPARα) (Waxman, 1999; Ingelman-
Sundberg, 2004).
All of these described regulatory mechanisms lead to the first
of instances of interindividual variability in drug response, where
a clear phenotypic consequence is evident in the population.
Another aspect to take in account is the inhibition effects
of CYP enzymes promoted by several drugs, chemicals, or
diet components. This effect can increase systemic exposure,
thereby causing severe toxic effects of the drug or of another
concomitantly administered therapeutic compound that is
metabolized by the same CYP(s) (Ludwig et al., 1999). The
competition between chemicals for CYP activity has resulted in
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unpredictable pharmacokinetic interactions and can be a cause
of drug–drug interactions, a major clinical problem.
Cytochrome P450 in Brain and Its Role in
Parkinson’s Disease
Most of these studies have been conducted in the liver which
is the major organ involved in drug metabolism due to the
high concentration of CYP in the endoplasmic reticulum of
hepatocytes. However, the CYP families involved in xenobiotic
metabolism are also expressed in extrahepatic tissues (i.e.,
intestine, brain, kidney). Since the expression of the majority of
the isoforms appears to be very low compared the predominant
expression in liver, and their role in overall total body
clearance is lower, the basal expression and up-regulation
in peripheral tissues can significantly affect local disposition
of drugs or endogenous compounds and thus modify the
pharmacological/toxicological effects or affect the distribution
of xenobiotics in human body. In the brain, the overall level
of CYP is ∼0.5–2% of that in liver microsomes (Miksys and
Tyndale, 2013) and could play a role in tissue- and/or cell-
specific sensitivity to certain drugs or xenobiotics. There have
been a number of suggestions that environmental toxins may
play a role in the pathogenesis of neurodegenerative disorders
by directly damaging neurons or through bioactivation of some
toxic compounds via CYPs (Riedl et al., 1999; Shahabi et al., 2008;
Miksys and Tyndale, 2009; Ferguson and Tyndale, 2011; Vaglini
et al., 2013).
In this context, it is underlined that studies with divergent
results are addressed toward the allele mutation of gene that
encodes CYP2D6. This isozyme is involved in the metabolism of
exogenous drugs and neurotoxins including 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP, a neurotoxin that can cause
selective dopaminergic neuronal damage) as well as endogenous
compounds including dopamine (Payami et al., 2001). Recently
Singh et al. (2014), in a study involving 70 PD patients, showed
that a allelic variants of CYP2D6 and glutathione transferase1
were significantly associated with an increase in PD risk, due to
a lower capability in the metabolism of neurotoxic compounds
such as pesticides. This study is in agreement with the a meta-
analysis performed by Lu et al. (2013) that demonstrated that an
allele polymorphism of CYP2D6 increases the risk of Parkinson’s
disease.
On the contrary, other studies did not support an association
between PD and mutations of the CYP2D6 and underline that
PD is most likely the result of interactions between multiple
genetic and environmental factors (Persad et al., 2003; Vilar et al.,
2007; Halling et al., 2008). Whatever the cause of PD and other
neurodegenerative disease, the knowledge of cytochrome P450
functions and metabolism is pivotal for its key roles in in vivo
drug action, and why it plays a crucial function in the metabolism
of toxic compounds.
Cytochrome P450-Dependent Metabolism
of MAO B Inhibitors and ASS234
In the COST Action CM1103, a new family of multi-target
molecules able to interact with AChE, as well as with MAO A
and B, was synthesized by Samadi et al. (2011). These compounds
bring together the benzylpiperidine and N-propargylamine
moieties present in the AChE inhibitor donepezil and the
MAO inhibitor PF9601N, respectively. The presence of propargyl
moiety in the molecule confers particular susceptibility in terms
of CYP-dependentmetabolism. It is well-known that the terminal
acetylenes can inhibit the CYP isoenzymes by alkylating the P450
prosthetic heme or by binding covalently to the protein with
only partial loss of the catalytic activity. Sharma et al. (1996)
demonstrated that both deprenyl and clorgyline are irreversible
inhibitors of CYP2B1, by a mechanism-based inactivation due
to the formation of a reactive intermediate based on their
propargyl group. A recent study suggests that deprenyl can
also inhibit CYP2B6 (Sridar et al., 2012). This isozyme is
involved in the metabolism of Bupropion, an antidepressant
often used to Parkinson’s disease patients in conjunction with
deprenyl, and its inhibition can lead to a potential drug
interactions.
However, the inhibition of CYP 2B1 and 2B6 does not
promote inhibition of CYP-dependent metabolism of the drug.
In fact deprenyl in humans, as well as in experimental animals,
is rapidly metabolized by the liver cytochrome CYP system,
forming mainly desmethydeprenyl and methamphetamine
(Baker et al., 1999; Dragoni et al., 2003b). These two compounds
are further metabolized to amphetamine. The CYP-dependent
metabolism showed a high hepatic clearance that justifies the
low half-life of the drug observed in vivo in humans (∼0.15 h)
(Sridar et al., 2012).
It is important to note that both primary deprenyl metabolites
can contribute to the therapeutic effect of the MAO-B
inhibitor. Desmethyldeprenyl, a less potent inhibitor of MAO-
B than the parent drug both in vitro and in vivo, is more
efficacious in protecting dopamine neurons against oxidative
stress damage (Olanow and Tatton, 1999). The other metabolite,
methamphetamine, is a more potent inhibitor of presynaptic
noradrenaline and dopamine uptake than the parent drug and it
has been suggested that this effect contributes to neuroprotection
(Sziráki et al., 1994).
These metabolic pathways are also active in the CNS, as
observed in vitro in microsomal preparations of monkey and
mouse brain (Dragoni et al., 2003a). In contrast to deprenyl,
PF9601N, the precursor of MTDL compounds studied in the
COST CM 1103 project (Bolea et al., 2011), showed significantly
lower liver clearance. The in vivo treatment of C57BL/6 mice
did not modify cytochrome P450 and b5 content, and did not
change NADPH-CYP-reductase or CYP2E1, 2A5, 1A1, 2B6, 3A
activities. Furthermore, CYP-dependent metabolism of PF9601N
by liver microsomes from either control or treated mice gave
rise only to the formation of the desmethyl metabolite, FA72
(Dragoni et al., 2007). This desmethyl compound promoted a
concentration-dependent inhibition of peroxinitrite oxidation
with an IC50 value lower than the parent compound and than
deprenyl. Furthermore, PF9601N and its metabolite were able to
strongly inhibit rat brain neuronal nitric oxide synthase, (NOS)
in contrast to observations with deprenyl, which caused a slight
decrease of the enzyme activity only at millimolar concentration
(Bellik et al., 2010).
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FIGURE 6 | Cytochrome P450-dependent metabolism of ASS234 in human (HLM) and rat (RLM) liver microsomal preparations. ASS234 (25 µM) was
incubated at 37◦C in phosphate buffer in the presence of microsomes for 30 min.
These observations led us to study the CYP-dependent
metabolism of ASS234 (Marco-Contelles et al., 2016). ASS234
was incubated in phosphate buffer with human or rat
hepatic microsomal preparations (HLM and RLM, respectively)
as previously reported (D’Elia et al., 2009). Samples were
analyzed by Agilent UHD Accurate-Mass Q-TOF LC/MS and
the experimental data obtained were elaborated using Mass-
MetaSite, a computer assisted method for the interpretation of
LC–MSMS data that combines prediction of a compound’s site
of metabolism (SoM) with the processing of MS spectra and
rationalization based on fragment analysis (Strano-Rossi et al.,
2014). The kinetic analysis indicated that the substrate depletion
followed a mono-exponential relationship either in presence of
HLM and RLM. RLM metabolized the compound at a higher
rate compared to HLM. In fact, after 30 min incubation only
23% of ASS234 was metabolized by human preparations, while
RLM preparations were able to metabolized more than the 80%
of initial amount (10 µM) of substrate (Simone et al., 2014).
The MS analysis of the products from ASS234 metabolism
showed two different pathways as shown in Figure 6. The
principal metabolite observed with HLM resulted in a compound
at [M-38]+ (m/z) indicating the formation of N-depropargylated
metabolite, in agreement with that observed for the CYP-
dependent metabolism of PF9601N (Dragoni et al., 2007). On the
contrary, in RLM preparations, the major metabolite resulted in
m/z equal to [M+16]+, which corresponded to the hydroxylated
derivative on the benzene ring. Other minor peaks were present
in both microsomal preparations and resulted in, as secondary
metabolites, the N-demethylated derivatives either on tertiary
amine or indole nitrogen. The in silico analysis indicated that
CYP2D6 and 2C19 are the major CYPs involved in the human
metabolism of ASS234 (Simone et al., 2014).
Taken together, this information clearly indicates that ASS234
is a poor CYP(s) substrate in human liver, that the resulting
metabolite should be not aMAO inhibitor, but that the inhibition
effect on AChE should remain. Furthermore, in accord with the
observations with PF9601N (Dragoni et al., 2007), the ASS234
CYP-dependent metabolite can be a more potent antioxidant and
NOS inhibitor than the parent compound.
However, the involvement of CYP2D6 and 2C19, two highly
genetic polymorphic cytochrome P450s, require more care due
to possible toxic effects of the parent compound having a
lower metabolic clearance. Moreover, the evidence that human
and rat present two different metabolic behaviors, in terms of
velocity and metabolite formation, underlines the differences
between species in CYP-dependent metabolism and the danger
of attempting to extrapolate results across species.
CONCLUSION
In the last century pharmacological research was driven to
discover highly selective drugs. This strategy has failed, in
part, because it is seen that the interaction with a single
target, either receptor or enzyme, can promote compensatory
adaptations in the living organisms leading to a failure of the
therapy. These observations and the discovery that different
pathologies have common aspects has led to the synthesis of new
molecules that can interact with multiple targets with the aim
to improved balance of efficacy and safety compared to single
targeting drugs.
We have reviewed the major targets for the assessment of
MTDL relevant to neurodegenerative diseases, giving examples
of compounds generated by our collaboratingmedicinal chemists
in COST Action CM1103. Mitochondria are highlighted as the
area of future interest but themany possible targets will have to be
refined to those most influential on progression in each specific
disease. It is becoming recognized, particularly for mitochondrial
function, that the cumulative effect of small inefficiencies can
trigger pathology under additional insult such as oxidative stress.
Recent advances in cell biology techniques have enabled the study
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of factors involved in mitochondrial dynamics. The processes
vital to mitochondrial health are also vital to neuronal survival
and will provide the challenge to discover new tools to prevent
neurodegeneration. When single target efficacy is achieved,
then new modalities can be added to MTDL for the ultimate
prevention of neuropathology.
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